CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Timothy M. Shannon sold 33,064 shares of the business’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $11.48, for a total transaction of $379,574.72. Following the sale, the director now directly owns 268 shares in the company, valued at approximately $3,076.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) traded up 3.01% during mid-day trading on Thursday, hitting $11.63. 52,512 shares of the company traded hands. The firm’s 50 day moving average price is $12.88 and its 200-day moving average price is $11.72. CytomX Therapeutics Inc. has a 1-year low of $9.10 and a 1-year high of $24.68. The stock has a market capitalization of $423.36 billion and a PE ratio of 0.49.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Several institutional investors have recently made changes to their positions in CTMX. Emerald Acquisition Ltd. acquired a new position in CytomX Therapeutics during the second quarter worth approximately $446,000. Swiss National Bank acquired a new position in CytomX Therapeutics during the second quarter worth approximately $230,000. California State Teachers Retirement System boosted its position in CytomX Therapeutics by 164.0% in the second quarter. California State Teachers Retirement System now owns 42,830 shares of the company’s stock worth $438,000 after buying an additional 26,607 shares during the last quarter. Private Advisor Group LLC acquired a new position in CytomX Therapeutics during the second quarter worth approximately $2,232,000. Finally, BlackRock Advisors LLC boosted its position in CytomX Therapeutics by 21,170.0% in the second quarter. BlackRock Advisors LLC now owns 542,384 shares of the company’s stock worth $5,541,000 after buying an additional 539,834 shares during the last quarter. Institutional investors own 51.59% of the company’s stock.

Separately, Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, November 8th.

About CytomX Therapeutics

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.